Asset Details
Do you wish to reserve the book?
Merkel Cell Polyomavirus Antibody in Tumor and Plasma Specimens in Patients with Merkel Cell Carcinoma
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Merkel Cell Polyomavirus Antibody in Tumor and Plasma Specimens in Patients with Merkel Cell Carcinoma
Do you wish to request the book?
Merkel Cell Polyomavirus Antibody in Tumor and Plasma Specimens in Patients with Merkel Cell Carcinoma
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Merkel Cell Polyomavirus Antibody in Tumor and Plasma Specimens in Patients with Merkel Cell Carcinoma
2025
Overview
Background
Merkel cell carcinoma (MCC) is associated with Merkel cell polyomavirus (MCPyV) infection. MCPyV antibodies (MCPyV-Ab) in plasma correlate with survival, while MCPyV-Ab within the tumor has never been investigated. This study evaluated plasma MCPyV-Ab and tumor MCPyV-Ab titers to evaluate their role in outcomes and prognostication.
Methods
A single-institution, prospective database was retrospectively reviewed for patients diagnosed with MCC from 2014 to 2021. MCPyV-Ab plasma and tumor titers, as well as patient and treatment factors, were collected. Two-year overall survival (OS) and disease-free survival (DFS) were examined based on MCPyV-Ab presence in tumor.
Results
Forty patients were identified, with a median follow-up of 27.6 months. Patients were stratified into four groups based on the presence of MCPyV-Ab in plasma (P+, P−) and tumor (T+, T−). Most patients (60.0%) were P−/T−. Of the remaining patients, 22.5% were P+/T+, 12.5% were P−/T+, and 5.0% were P+/T−. Two-year DFS of the P−/T− group was 16.6 months, which was not different from the other groups (
p
= 0.79). Two-year OS of P−/T− was 18.3 months, and 2-year OS of P−/T+ was 28.1 months, which was similar between groups (
p
= 0.80).
Conclusions
Most patients P+ for MCPyV had antibody-positive tumors (T+), and P− patients were also T−; however, there was a subset of patients where plasma and tumor antibody findings were incongruent. Patients with MCPyV-Ab in either plasma or tumor had a trend toward improved 2-year DFS and OS, but was limited by a small cohort. This study offers an exploratory investigation into the relationship between plasma and tumor antibodies to MCPyV on which to base future work.
Publisher
Springer International Publishing,Springer Nature B.V
Subject
/ Carcinoma, Merkel Cell - blood
/ Carcinoma, Merkel Cell - immunology
/ Carcinoma, Merkel Cell - pathology
/ Carcinoma, Merkel Cell - virology
/ Female
/ Humans
/ Male
/ Medicine
/ Melanoma
/ Merkel cell polyomavirus - immunology
/ Oncology
/ Plasma
/ Polyomavirus Infections - blood
/ Polyomavirus Infections - immunology
/ Polyomavirus Infections - virology
/ Surgery
/ Tumor Virus Infections - blood
/ Tumor Virus Infections - complications
/ Tumor Virus Infections - immunology
/ Tumor Virus Infections - virology
/ Tumors
